We are live on
!
Find out more
CC
Casdin Capital Portfolio holdings
AUM
$1.32B
1-Year Est. Return
76.62%
This Fund
S&P 500
This Quarter
Est. Return
+11.22%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.1B
AUM Growth
-$126M
(-10%)
Cap. Flow
-$161M
Cap. Flow
% of AUM
-14.63%
Top 10 Holdings %
Top 10 Hldgs %
85.29%
Holding
45
New
1
Increased
9
Reduced
12
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Structure Therapeutics
GPCR
|
+$11.5M |
| 2 |
Relay Therapeutics
RLAY
|
+$6.84M |
| 3 |
Eli Lilly
LLY
|
+$6.61M |
| 4 |
Illumina
ILMN
|
+$4.06M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$3.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$31.1M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$28.9M |
| 3 |
BioLife Solutions
BLFS
|
+$22.5M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$16M |
| 5 |
Intellia Therapeutics
NTLA
|
+$14.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Absci
ABSI
$1.34B
| $2.5M | 0.23% |
973,260
| – | – |
|
27
Pacific Biosciences
PACB
$441M
| $897K | 0.08% |
723,767
| – | – |
|
28
Recursion Pharmaceuticals
RXRX
$1.69B
| $837K | 0.08% |
165,323
| – | – |
|
29
Century Therapeutics
IPSC
$357M
| $686K | 0.06% |
1,228,190
-1,984,126
| -62% | -$1.06M |
|
|
CTNM
30
Contineum Therapeutics
CTNM
$599M
| $589K | 0.05% |
148,333
| – | – |
|
31
Ginkgo Bioworks
DNA
$584M
| $411K | 0.04% |
36,493
| – | – |
|
32
Monte Rosa Therapeutics
GLUE
$1.3B
| $388K | 0.04% |
86,014
| – | – |
|
33
Tenaya Therapeutics
TNYA
$158M
| $221K | 0.02% |
361,969
-6,371,002
| -95% | -$3.24M |
|
|
BPMC
34
DELISTED
Blueprint Medicines
BPMC
| – | – |
-326,378
| Closed | -$28.9M |
|
35
Dyne Therapeutics
DYN
$4.71B
| – | – |
-100,000
| Closed | -$1.05M |
|
36
GE HealthCare
GEHC
$31.5B
| – | – |
-100,000
| Closed | -$8.07M |
|
|
KRON
37
DELISTED
Kronos Bio
KRON
| – | – |
-123,839
| Closed | -$102K |
|
38
Moderna
MRNA
$21.9B
| – | – |
-225,000
| Closed | -$6.38M |
|
|
39
Intellia Therapeutics
NTLA
$1.5B
| – | – |
-2,000,000
| Closed | -$14.2M |
|
40
Solid Biosciences
SLDB
$790M
| – | – |
-775,000
| Closed | -$2.87M |
|
41
Teladoc Health
TDOC
$1.21B
| – | – |
-300,000
| Closed | -$2.39M |
|
42
Tango Therapeutics
TNGX
$4.43B
| – | – |
-125,000
| Closed | -$171K |
|
|
TSVT
43
DELISTED
2seventy bio
TSVT
| – | – |
-2,000,000
| Closed | -$9.88M |
|
44
Verastem
VSTM
$500M
| – | – |
-600,000
| Closed | -$3.62M |
|
|
ONC
45
BeOne Medicines Ltd
ONC
$32.6B
| – | – |
-40,000
| Closed | -$10.9M |
|
Similar funds
MDSL
CP
HCM
MRL
SWM
B
WGAM
CRAM
Casdin Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Casdin Capital held 45 positions worth $1.1B, down 10% from $1.22B the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Casdin Capital withdrew a net $161M in Q2 2025, closing 12 positions and reducing 12 holdings. Its most notable exit was Blueprint Medicines, an estimated $28.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Casdin Capital opened a new position in Eli Lilly worth $6.63M.
- Casdin Capital's largest Q2 2025 buy was Eli Lilly: 8,500 shares worth $6.63M.
- Casdin Capital added most to Structure Therapeutics in Q2 2025, an estimated $11.5M increase.
- Casdin Capital's biggest Q2 2025 reduction was Revolution Medicines, cutting an estimated $31.1M.
- Casdin Capital fully exited Blueprint Medicines in Q2 2025, selling an estimated $28.9M.
- Casdin Capital's ten largest holdings make up 85% of its $1.1B portfolio in Q2 2025.
- Casdin Capital opened 1 new position and closed 12 in Q2 2025.
- Casdin Capital's portfolio value fell 10% quarter-over-quarter to $1.1B.
Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.